

Priority Health Medicare prior authorization form

Fax completed form to: 877.974.4411 toll free, or 616.942.8206 ■ Medicare Part B Medicare Part D This form applies to: Expedited request ☐ Standard request This request is: Your request will be expedited if you haven't gotten the prescription and Priority Health Medicare determines, or your prescriber tells us, that your life or health may be at risk by waiting. Humira® (adalimumab) Member Last Name: DOB: _____ Gender: ____ Primary Care Physician: Prov. Phone: _____ Prov. Fax: _____ Requesting Provider: Provider Address: Contact Name: Provider NPI: Provider Signature: **Product Information** ☐ New request ☐ Continuation request Drug product: ☐ Humira Pediatric Crohn's Starter Kit Start date (or date of next dose): ☐ Humira Starter Kit Date of last dose (if applicable): Dosing frequency: ☐ Humira Pre-filled Syringe Kit ☐ Humira Pen Injector Kit

Prior authorization criteria

The following requirements need to be met before this drug is covered by Priority Health Medicare. These requirements have been approved by the Centers for Medicare and Medicaid Services (CMS), but you may ask us for an exception if you believe one or more of these requirements should be waived.

For this drug to be covered, the patient must meet the following criteria:

- Must be used for a medically accepted indication*
- For a diagnosis of ankylosing spondylitis:
 - Must have presence of disease for at least 4 weeks
 - Must have a BASDAI score of at least 4
 - Must have documented trial and failure (defined as an inability to improve symptoms) or intolerance to 1
- For a diagnosis of Crohn's disease, psoriatic arthritis, rheumatoid arthritis, or ulcerative colitis:
 - Must have a documented trial and failure (defined as an inability to improve symptoms) or intolerance to one non-biologic immunomodulator (e.g., azathioprine, 6-mercaptopurine, methotrexate)
- For a diagnosis of psoriasis:
 - Must first have > 5% of body surface area affected (unless hands, feet, head, neck, or genitalia are affected)
 - Must have a documented trial and failure (defined as an inability to improve symptoms) or intolerance to one topical or one non-biologic immunomodulator (e.g., methotrexate, cyclosporine, acitretin)
- For a diagnosis of hidradenitis suppurativa:
 - Must first have a documented trial and failure (defined as an inability to improve symptoms) or intolerance with systemic or topical antibiotic therapy
- 6. Prescriber is a specialist or has consulted with a specialist for the condition being treated



- 7. Must not use Humira in combination with other biological drugs (e.g., Enbrel)
- 8. Must be 2 years of age or older

Medically accepted indication*

Additional information

This drug is only covered under Medicare Part D when it is used for a medically accepted indication. A medically accepted indication is a use of the drug that is either.

- approved by the Food and Drug Administration. (That is, the Food and Drug Administration has approved the drug for the diagnosis or condition for which it is being prescribed.)
- or supported by certain reference books. (These reference books are the American Hospital Formulary Service Drug Information, the DRUGDEX Information System, and Lexi-Drugs.)

No	te: When criteria are	met, coverage duration is 1 year	
Pr	ecertification Doc	umentation	
A.	☐ Yes. ☐ No. Are yo	the prescriber a specialist or has consulted with a specialist for the condition being treated? Yes. No. Are you asking for an exception to this requirement? Yes. Rationale for exception: No	
В.	☐ No. ☐ Yes. Are yo	ed in combination with other biological drugs (e.g., Enbrel)? ou asking for an exception to this requirement? es. Rationale for exception: 0	
C.	Answer the applic	able questions in the table below.	
	Condition	Additional requirements for specific indications	
	(F	Please check the appropriate box to indicate the patient has met the required criteria	

1. Has the patient had a documented trial and failure (defined as an inability to improve

symptoms) or intolerance with systemic or topical antibiotic therapy?

 ■ No. Are you requesting an exception to the criteria? Yes. Rationale for exception:

☐ Hidradenitis

suppurativa

Yes. Check all that apply.

□ No

☐ Topical antibiotic therapy

☐ Systemic antibiotic therapy



☐ Psoriatic arthritis☐ Rheumatoid arthritis☐ Crohn's disease☐ Ulcerative colitis	1. Has the patient had a documented trial and failure (defined as an inability to improve symptoms) or intolerance to 1 non-biologic immunomodulator? Yes. No. Are you requesting an exception to the criteria? Yes. Rationale for exception: No
☐ Ankylosing spondylitis	1. Does the patient have a BASDAI score of at least 4? Yes. BASDAI score: No. Are you requesting an exception to the criteria? Yes. Rationale for exception: No 2. Has the patient had presence of disease for at least 4 weeks? Yes Yes No. Are you requesting an exception to the criteria? Yes. Rationale for exception: No 3. Has the nationt had a documented trial and failure (defined as an inability to improve
	3. Has the patient had a documented trial and failure (defined as an inability to improve symptoms) or intolerance with 1 NSAID? Yes No. Are you requesting an exception to the criteria? Yes. Rationale for exception: No
	 1. Is ≥ 5% of BSA affected or are hands, feet, head, neck, or genitalia affected?
☐ Plaque psoriasis	 2. Has the patient had a documented trial and failure (defined as an inability to improve symptoms) or intolerance to 1 topical or 1 non-biologic immunomodulator? Yes. Check all that apply. Topical drug One non-biologic immunomodulator (e.g., methotrexate, cyclosporine, acitretin). No. Are you requesting an exception to the criteria? Yes. Rationale for exception:
☐ Other condition	1. The patient's condition is: 2. Rationale for use is:



Priority Health Medicare Exception Request (exceptions to the above criteria)
Do you believe one or more of the prior authorization requirements should be waived? — Yes — No If yes, you must provide a statement explaining the medical reason why the exception should be approved.
Would Humira likely be the most effective option for this patient? ☐ Yes ☐ No If yes, please explain why:
If the patient is currently using Humira, would changing the patient's current regimen likely result in adverse effects for the patient? Yes No If yes, please explain: